KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
Want to see KALV full AI Analyst Report?
KALV Stock Chart & Stats
$20.48
-$0.39(-4.51%)
At close: 4:00 PM EST
$20.48
-$0.39(-4.51%)
Day’s Range― - ―
52-Week Range$9.83 - $21.31
Previous CloseN/A
Volume49.40K
Average Volume (3M)1.19M
Market Cap
$995.25M
Enterprise Value$1.06B
Total Cash (Recent Filing)$300.21M
Total Debt (Recent Filing)$284.21M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Jul 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding51,222,490
10 Day Avg. Volume1,074,112
30 Day Avg. Volume1,185,521
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)7.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.46
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue14.08
Enterprise Value/Gross Profit20.50
Enterprise Value/Ebitda-5.15
Forecast
1Y Price Target
$35.57Price Target Upside73.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.95
Revenue Forecast (FY)$204.74M
Bulls Say, Bears Say
Bulls Say
Commercial Launch And Prescriber AdoptionStrong US launch momentum with start form activity and broad prescriber adoption has outpaced analyst forecasts, supporting a faster commercial ramp potential.
Patient Retention And Refill DurabilityRefill prescriptions represent the majority of use and revenue, indicating durable patient retention and repeat usage that can sustain ongoing sales.
Payer Coverage And ReimbursementAnalyst and payer feedback point to favorable reimbursement from large payers and navigable access with many plans, improving the likelihood that starts convert into commercially covered patients.
Bears Say
Competitive Threat From GenericsPotential competition from generic icatibant could pressure uptake and create uncertainty around converting early prescription interest into sustained commercial sales.
International Pricing And Revenue LimitationsSignificant ex‑US pricing discounts and reduced non‑US revenue expectations could limit the contribution of international markets to overall revenue growth.
Sustainability Of High Refill IntensityDurability of elevated refill rates is uncertain as the treated population expands into lower‑burden patients, which could lower average use per patient over time.
KalVista Pharmaceuticals News
KALV FAQ
What was KalVista Pharmaceuticals’s price range in the past 12 months?
KalVista Pharmaceuticals lowest stock price was $9.83 and its highest was $21.30 in the past 12 months.
What is KalVista Pharmaceuticals’s market cap?
KalVista Pharmaceuticals’s market cap is $995.25M.
When is KalVista Pharmaceuticals’s upcoming earnings report date?
KalVista Pharmaceuticals’s upcoming earnings report date is Jul 02, 2026 which is in 69 days.
How were KalVista Pharmaceuticals’s earnings last quarter?
KalVista Pharmaceuticals released its earnings results on Mar 17, 2026. The company reported -$0.92 earnings per share for the quarter, missing the consensus estimate of -$0.672 by -$0.248.
Is KalVista Pharmaceuticals overvalued?
According to Wall Street analysts KalVista Pharmaceuticals’s price is currently Undervalued.
Does KalVista Pharmaceuticals pay dividends?
KalVista Pharmaceuticals does not currently pay dividends.
What is KalVista Pharmaceuticals’s EPS estimate?
KalVista Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals has 51,222,490 shares outstanding.
What happened to KalVista Pharmaceuticals’s price movement after its last earnings report?
KalVista Pharmaceuticals reported an EPS of -$0.92 in its last earnings report, missing expectations of -$0.672. Following the earnings report the stock price went down -1.546%.
Which hedge fund is a major shareholder of KalVista Pharmaceuticals?
Currently, no hedge funds are holding shares in KALV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
KalVista Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.57 (73.69% Upside)
$35.57 (73.69% Upside)
Blogger Sentiment
Bullish
KALV Sentiment 67%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 428.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.66%
12-Months-Change
Fundamentals
Return on Equity
-444.41%
Trailing 12-Months
Asset Growth
33.74%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
KALV Stock 12 Month Forecast
Average Price Target
$35.57
▲(73.69% Upside)
Technical Analysis
Savara
―
Arvinas Holding Company
―
Gossamer Bio
―
Compass Therapeutics
―
Bicara Therapeutics Inc.
―
Ownership Overview
Currently, No data available
---